UC Davis cancer center ranks first in clinical trials enrollment

August 03, 2004

(SACRAMENTO, Calif.) -- For the third year in a row, UC Davis Cancer Center ranked first among the 283 research institutions in the Southwest Oncology Group for the number of patients enrolled in cancer clinical trials. The cancer center and its affiliates enrolled 185 patients in SWOG trials between January and December 2003.

The Cancer Center also ranked eighth among the 250 research institutions in the Radiation Therapy Oncology Group for the number of patients enrolled in cancer clinical trials during the first quarter of this year.

"Advances in cancer treatment depend upon clinical trials," said Kelly Avery, clinical research administrator at UC Davis Cancer Center. "We're very proud of the number and variety of trials we have open, and with our ability to provide investigational treatments to cancer patients in our region."

Sponsored by the National Cancer Institute, the Southwest Oncology Group is one of the largest adult cancer clinical trials organizations in the world. Its membership consists of nearly 4,000 of the nation's leading physicians at 283 institutions throughout the United States and Canada.

The Radiation Therapy Oncology Group, established nearly 30 years ago, comprises 250 major cancer research institutions in the United States and Canada. The group has 40 active clinical trials that involve radiation therapy either alone or in conjunction with surgery, chemotherapy or both.

An individual cancer center rarely has the numbers of patients needed to determine whether a new cancer treatment is safe and effective. To solve this problem, the National Cancer Institute funds 12 cooperative research groups capable of conducting large, multi-center trials of investigational treatments. SWOG and RTOG are two of the largest of these cooperative groups.

UC Davis Cancer Center has one of the nation's most vigorous clinical trials programs. About 16 percent of new cancer patients seen at the Cancer Center participate in a clinical trial.

Nationally, less than 3 percent of adult cancer patients enroll in clinical trials each year, a rate that hasn't improved in more than two decades.

Low enrollment in clinical trials can prolong drug development and delay patient access to potentially beneficial new agents. The Cancer Leadership Council, Cancer Research Foundation of America, Coalition of National Cancer Cooperative Groups, Oncology Nursing Society and American Society of Clinical Oncology together have set a goal of doubling participation in cancer clinical trials nationwide over the next three to five years.

Cancer patients can learn more about clinical trials offered at UC Davis Cancer Center by calling 800-2-UCDAVIS or visiting the Web at http://www.ucdaviscancerclinicaltrials.org.
-end-
UC Davis Cancer Center is the only National Cancer Institute-designated cancer center between San Francisco and Portland, Ore. It is affiliated with Fremont-Rideout Cancer Center in Marysville and Mercy Cancer Center in Merced, and serves more than 3,000 new patients a year from throughout Central and Northern California, southern Oregon and western Nevada.

Copies of all news releases from UC Davis Health System are available on the Web at http://www.ucdmc.ucdavis.edu/newsroom

University of California - Davis Health System

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.